Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 7Recruiting 2Active not recruiting 2Withdrawn 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Small Cell Lung Carcinoma 27Lymphoma, Large B-Cell, Diffuse 10Lung Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, Non-Hodgkin 6Lymphoma, B-Cell 6Hodgkin Disease 6Burkitt Lymphoma 6Neuroblastoma 5Medulloblastoma 5Neoplasms, Germ Cell and Embryonal 4Leukemia, Myeloid, Acute 4Small Cell Lung Cancer Extensive Stage 3Seminoma 3Retinoblastoma 3Recurrence 3Ovarian Neoplasms 3Multiple Myeloma 3Lymphoma 3Carcinoma, Neuroendocrine 3Brain Neoplasms 3Wilms Tumor 2Urinary Bladder Neoplasms 2Teratoma 2Sarcoma, Ewing 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Plasmablastic Lymphoma 2Neuroectodermal Tumors, Primitive 2Lymphoma, T-Cell 2Lymphoma, Mantle-Cell 2

Interventions

lutetium Lu 177 dotatate 2Temozolomide 2ONC206 2Etoposide 2Cyclophosphamide 2Bevacizumab 2olaparib 1neratinib 1ibrutinib 1fenofibric acid 1etoposide phosphate 1brigatinib 1Watchful Waiting 1Thalidomide 1Restraint, Physical 1Radiotherapy 1Radiation 1Magnetic Resonance Spectroscopy 1Linear Energy Transfer 1Irinotecan 1Elasticity Imaging Techniques 1Cytarabine 1Celecoxib 1Automobiles 11-methyltryptophan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Ependymoma × Etoposide × Clear all
NCT01356290 2026-02-23

MEMMAT

Medical University of Vienna

Phase 2 Recruiting
232 enrolled
CNS

Ependymoma, Medulloblastoma, Recurrence

NCT05106296 2026-01-09

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

Augusta University

Phase 1 Recruiting
37 enrolled
CNS

Brain Neoplasms, Ependymoma, Glioblastoma, Medulloblastoma, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡